NCT04237623 2026-04-16
GM-CSF With Post-Transplant Cyclophosphamide
Northside Hospital, Inc.
Phase 2 Recruiting
Clinical Trials
12 trialsNCT07078604 2026-04-07
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT05544968 2026-04-03
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Recruiting
NCT06450041 2026-03-23
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT06202066 2026-03-11
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06626516 2025-11-28
Tebentafusp-tebn With LDT in Metastatic UM
Thomas Jefferson University
Phase 1/2 Recruiting
NCT07027748 2025-07-14
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT04211675 2025-05-13
STING
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT05101356 2024-05-21
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
University of California, Davis
Phase 1/2 Recruiting
NCT05344209 2023-11-09
LUNGVAC
Vestre Viken Hospital Trust
Phase 2 Recruiting